Physician profile
David Stevens
NPI 1770017683
$2,681.56
in general payments reported to CMS, 2019-2025
36 companies · $847 in 2025
The $847 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $22.60 · 2023: $597 · 2024: $1,215 · 2025: $847.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,659.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,658.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $476.33 | 2023-2025 | Botox, Qulipta, Ubrelvy |
| Pfizer INC. | $199.68 | 2024-2025 | |
| Lilly USA, LLC | $141.03 | 2023-2024 | Amyvid, Emgality, Reyvow |
| Biogen, INC. | $134.93 | 2023-2024 | Vumerity, Tysabri, Skyclarys |
| Emd Serono, INC. | $133.63 | 2024 | |
| Ucb, INC. | $131.99 | 2023 | Fintepla, Briviact |
| Neurocrine Biosciences, INC. | $107.01 | 2023-2024 | Ingrezza |
| Argenx US, INC. | $105.90 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Tanabe Pharma America, INC. | $86.07 | 2022-2025 | Radicava |
| Boston Scientific Corporation | $86.01 | 2025 | Rhythmia Mapping System |
| Novartis Pharmaceuticals Corporation | $83.60 | 2024-2025 | |
| Eisai INC. | $80.05 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $78.33 | 2024 | |
| Alexion Pharmaceuticals, INC. | $76.52 | 2023-2025 | Ultomiris |
| Vanda Pharmaceuticals INC. | $71.61 | 2024-2025 | Ponvory |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $67.79 | 2024-2025 | Valtoco |
| Merz Pharmaceuticals, LLC | $58.67 | 2024-2025 | Xeomin |
| Lundbeck LLC | $56.13 | 2023-2025 | Vyepti, Rexulti |
| Amgen INC. | $55.56 | 2025 | Uplizna |
| Tg Therapeutics, INC. | $38.31 | 2024 | |
| Sk Life Science, INC. | $34.94 | 2024 | |
| Abbott Laboratories | $34.20 | 2025 | Infinity |
| Amneal Pharmaceuticals LLC | $33.57 | 2025 | Crexont |
| Avadel Cns Pharmaceuticals, LLC | $32.51 | 2025 | Lumryz |
| Otsuka America Pharmaceutical, INC. | $29.66 | 2023 | Rexulti |
| Ani Pharmaceuticals, INC. | $27.97 | 2024 | Purified Cortrophin Gel |
| Genentech USA, INC. | $27.52 | 2024 | Ocrevus |
| Genzyme Corporation | $26.13 | 2025 | |
| Ge Healthcare | $23.01 | 2023 | |
| Mdd US Operations, LLC | $21.98 | 2024 | Apokyn |
| Harmony Biosciences LLC | $21.83 | 2024 | |
| Livanova USA, INC. | $21.34 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Genentech, INC. | $21.21 | 2024 | Ocrevus |
| Mallinckrodt Hospital Products INC. | $20.53 | 2025 | Acthar |
| Kyowa Kirin, INC. | $18.98 | 2023 | Nourianz |
| Teva Pharmaceuticals USA, INC. | $17.03 | 2023 | Austedo Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Stevens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.